Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Mouse/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-PRB4 (178-247) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
PRB4Uniprot ID=PRB4_HUMAN" |
Immunogen Region: |
178-247 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 178-247 of human PRB4 (NP_002714.2). |
Immunogen Sequence: |
SPPGKPQGPPQQEGNKPQGP PPPGKPQGPPPAGGNPQQPQ APPAGKPQGPPPPPQGGRPP RPAQGQQPPQ |
Post Translational Modifications | N-glycosylated. Proteolytically cleaved at the tripeptide Xaa-Pro-Gln, where Xaa in the P(3) position is mostly lysine. The endoprotease may be of microbial origin. Pyroglutamate formation found on at least Gln-46, Gln-48, Gln-67, Gln-88.Gln-90.Gln-193.Gln-288 Gln-214 and Gln-295, preferentially in diabetic, and head and neck cancer patients. |
Protein Name | Basic Salivary Proline-Rich Protein 4Salivary Proline-Rich Protein PoParotid O ProteinSalivary Proline-Rich Protein Ii-1 Cleaved Into - Protein N1 - Glycosylated Protein A - Peptide P-DProline-Rich Peptide Ib-5 |
Cellular Localisation | Secreted |
Alternative Antibody Names | Anti-Basic Salivary Proline-Rich Protein 4 antibodyAnti-Salivary Proline-Rich Protein Po antibodyAnti-Parotid O Protein antibodyAnti-Salivary Proline-Rich Protein Ii-1 Cleaved Into - Protein N1 - Glycosylated Protein A - Peptide P-D antibodyAnti-Proline-Rich Peptide Ib-5 antibodyAnti-PRB4 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance